Speedus Corp (SPDE) Fair Value & Analysis

Healthcare · US · Market cap $416

Below-average quality, currently priced close to our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.

How to read this chart

60‑month range $0.0001 – $0.0260 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Speedus Corp (SPDE) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Trailing-twelve-month revenue stands at $551K. Revenue declined 29.7% year over year. Fundamentals as of Aug 22, 2026

The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at 0%, SPDE screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Speedus Corp., through its subsidiaries, engages in the development of diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists, and other healthcare professionals in the United States.

Full company description

Speedus Corp., through its subsidiaries, engages in the development of diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists, and other healthcare professionals in the United States. The company offers computer-aided medical devices and telemedicine based delivery systems, including Zargis Cardioscan device, a non-invasive diagnostic support solution that automatically analyzes acoustical data from a patient to determine whether or not the patient possesses a suspected diastolic or systolic murmur; ZargisTelemed portal; and Signal X6 device, which records heart and lung sounds from six adhesive acoustic sensors. It also develops and markets ultra-high speed storage systems comprising JetX10 acceleration appliance, JetPod, and JetNode expansion chassis for server networks and other applications. In addition, the company offers local multipoint distribution service license, an FCC commercial operating license, which covers between 150"300 MHz of spectrum in the New York City area. Further, it holds investments in a portfolio of marketable securities and in equity and debt instruments of non-publicly held companies. The company was formerly known as SPEEDUS.COM, Inc. and changed its name to Speedus Corp. in May 2002. Speedus Corp. was founded in 1995 and is based in Freehold, New Jersey.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2004 – FY2009 · reported fiscal years

Speedus Corp reported revenue of $461K in FY2009 versus $1.0M in FY2005, a compound −18.4%/yr. Reported net income was −$2.8M in FY2009.

Watch SPDE: get an alert when its fair value changes →

Peer Group

Medical Instruments & Supplies · 204 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.